SK pharmteco bets $200M-plus on US small molecule and peptide expansion
What's the deal? SK pharmtecoDealroom has a profile for this one. Try Dealroom → will invest more than $200 million over five years to expand and upgrade its US development and manufacturing infrastructure for small molecules and peptides. The contract development and manufacturing organisation (CDMO) announced the plan on September 30, 2026. It expects the investment to create 100 long-term, high-skilled US jobs.
What's the endgame? SK pharmteco will build new development laboratories, add GMP kilo-scale peptide capacity — set to come online in late 2026 — and construct new small-molecule manufacturing suites. It also plans upgrades to utilities, logistics, digital infrastructure, and green technology.
What does the company do? SK pharmteco is a global CDMO with sites across the US, Europe, and South Korea, focused on small molecules, peptides, and viral vectors. It is a subsidiary of SK Inc.Dealroom has a profile for this one. Try Dealroom →, part of SK GroupDealroom has a profile for this one. Try Dealroom →, South Korea's second-largest conglomerate.
Why now? The company says it is responding to "unprecedented demand" from its customer base. The US push also aims to secure a more resilient supply chain for active pharmaceutical ingredients (APIs).
Chief executive officer Joerg Ahlgrimm called the plan "a transformative milestone," adding that the company wants customers to have "a highly reliable, sustainable, and cutting-edge partner from early-stage development through full commercialization."
The bigger picture: The US spending extends an active global build-out. SK pharmteco recently put $6 million into its California facility for peptide development, opened two manufacturing facilities in Ireland, and committed $260 million to expand small molecule and peptide production in South Korea.
The signal: Peptide demand is reshaping CDMO investment, and SK pharmteco is adding capacity on multiple continents to capture it. The emphasis on domestic US manufacturing also reflects a wider industry drive to localise pharmaceutical supply chains.
Read more: newsbreakmiddleeast.com
Image credit: Generated with Gemini
